Abstract
Alterations in mitochondrial metabolism in obesity may indicate disrupted communication between mitochondria and nucleus, crucial for adapting to changing metabolic demands. Epigenetic modifications, particularly DNA methylation, may influence this intricate interplay, though the specifics remain poorly understood. Leveraging data from the subcohort of the Finnish Twin Cohort (n=173; 86 full twin pairs) that includes comprehensive measurements of obesity-related outcomes, mitochondrial DNA quantity (mtDNAq) and nuclear DNA methylation levels in adipose and muscle tissue, we identified one locus at SH3BP4 (cg19998400) significantly associated with mtDNAq in adipose tissue (FDR<0.05). SH3BP4 methylation correlated with its gene expression. Additionally, 14 out of the 35 obesity-related traits displayed significant associations with both SH3BP4 methylation and mtDNAq in adipose tissue. Using the method that infers causality from examination of familial confounding (ICE FALCON) our data suggests that mtDNAq, insulin sensitivity and certain body fat measures are causal to SH3BP4 methylation. The examination of mtDNAq and obesity-related traits suggested causation from mtDNAq to obesity which could not, however, be distinguished from potential unmeasured within-individual confounding. In conclusion, our findings underscore the impact of mtDNAq on DNA methylation and expression of the SH3BP4 gene within adipose tissue, with potential implications for obesity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is supported by the following funds: University of Helsinki, Faculty of Medicine, Doctoral School of Population Health (DOCPOP) (A.H.), an Australian Government Research Training Program (RTP) Scholarship (V.F.C.E.), Academy of Finland (#328685, #307339, #297908 and #251316, M.O; # 338417, S.H.; #335443, #314383, #266286, K.H.P.), Academy of Finland Center of Excellence in Complex Disease Genetics (#352792) (J.K.) and Centre of Excellence in Research on Mitochondria, Metabolism and Disease (FinMIT) (#272376) (K.H.P.), Sigrid Juselius Foundation (M.O.), Liv o Halsa society (M.O.), Minerva Foundation (M.O.), Novo Nordisk Foundation (grants #NNF20OC0060547, #NNF17OC0027232, #NNF10OC1013354, K.H.P.; #NNF23SA0083953, S.H.), National Health and Medical Research Council Investigator Grant (GNT2017373) (S.Li), Diabetes Research Foundation (S.H., K.H.P.), Paulo Foundation (S.H., K.H.P.), Gyllenberg Foundation (K.H.P.) Finnish Medical Foundation (K.H.P.), University of Helsinki and Helsinki University Hospital (K.H.P., S.H.) and Government Research Funds (K.H.P.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of the Hospital District of Helsinki and Uusimaa approved the protocols of this FTC substudy data collections, and all participants provided their written informed consent. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
RNA sequencing data is part of the ‘Twin Study’ and deposited with the Biobank of the Finnish Institute for Health and Welfare (https://thl.fi/en/research-and-development/thl-biobank/for-researchers/sample-collections/twin-study). For details on accessing the data, see: https://thl.fi/en/research-and-development/thl-biobank/for-researchers/application-process. The rest of the FTC data is not publicly available due to the restrictions of informed consent. However, the FTC data is available through the Institute for Molecular Medicine Finland (FIMM) Data Access Committee (DAC) (fimmdac{at}helsinki.fi) for authorized researchers who have IRB/ethics approval and an institutionally approved study plan.
